Hone Health Review: It Sells Men a Peptide Whose Own FDA Label Says It Is Not For Men

What Hone gets right, which is the structural part

It would be easy to file this company under the usual template, and it does not fit.

Read Hone's terms of use and you find disclosures most of this category will not make. The medical practice is named: Broad Health P.A., 154 W. 14th Street, 6-110, New York. The platform states its own limits: "Neither Hone nor Broad Health sell, manufacture, or dispense prescription medications. The third party pharmacies, and not Hone or Broad Health, set their own prices for medications."

The billing clause promises an itemised invoice separating "the actual charges by Broad Health for the services, the pharmacy or other supplement provider for their products, and us for the online membership fee." Most competitors quote one blended monthly number precisely so that separation is invisible.

And then the sentence that no other provider covered on this site publishes: "if you receive a prescription for a medication, you always have the option to instruct Broad Health to transmit that prescription to the pharmacy of your choice."

That single clause breaks the closed loop the whole business model in this category depends on. It means a Hone patient can take the prescription to a pharmacy they can look up, whose licence they can check, and whose prices they can compare. It deserves to be said plainly, because it is better than anything in this review is about to say.

Ten million characters, and not one word about sterility

Here is the finding that the good disclosure makes stranger rather than better.

Hone's page sitemap lists 109 URLs. On August 9, 2026, 107 of them downloaded successfully — two /edge/ blog hubs return HTTP 500 — for a corpus of 10,064,765 characters. That is the published marketing site, entire.

Searched case-sensitively across all of it, these strings occur zero times: "USP", "sterile", "sterility", "certificate of analysis", "COA", "503A", "503B", "outsourcing facility", "third-party tested", "lot number", "purity". The string "potency" occurs once, in the phrase "Rosuvastatin is a high-potency statin".

This is not a failure to locate a quality page. There is no quality claim in the site to locate. Hone does not say its preparations are tested, does not name a standard, does not state a potency tolerance, does not publish a lot report, and never states whether the vial came from a 503A pharmacy or a 503B outsourcing facility — a distinction that decides what inspection regime stands behind it. If that distinction is unfamiliar, it is worth ten minutes: 503A and 503B are not two words for the same thing, and a certificate of analysis is a document, not a posture.

What Hone publishes instead is regulatory-status language — the compounded-drug disclaimer, which is correct and well placed. But that sentence describes what nobody has checked. It is not a substitute for saying what anybody has.

The one quality assertion anywhere on the property sits on a page that cannot sell you anything. honehealth.com/peptides-waitlist promises "Evidence based, clinical safety reviewed · Compounded in the USA · NABP-accredited pharmacies". Those two waitlist pages are the only place the string "NABP" appears in the entire corpus. The claim exists; it is attached to the products that do not yet exist.

Two disclaimers, sorted by product

Now the detail that is small, entirely verifiable, and says more about how this site was assembled than any of the copy does.

Across the 107 pages, two different regulatory disclaimers are in use.

Eighteen pages carry the drug version: "This is a compounded product and has not been approved by the FDA. The FDA does not verify the safety or effectiveness of compounded drugs." Sermorelin has it. PT-141 has it. Compounded liraglutide has it. Testosterone, phentermine, enclomiphene, naltrexone, topiramate, bupropion — all have it.

Five pages carry the dietary-supplement version instead: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

No page carries both. And the five are: the NAD+ injection, the glutathione injection, the B12 injection, prescription omega-3, and metformin.

Two of those are compounded prescription injectables. One is metformin, an approved prescription drug that has been in American pharmacies since 1995. All five are being described in the language Congress wrote for dietary supplements, on pages that in the same paragraph say "Prescription products require an online evaluation with a licensed medical professional."

Nothing about this is deceptive on its face — the supplement formula is arguably more cautious, not less. But it is the wrong instrument, applied to the two products on the site with the weakest evidence behind them, and it replaces the one sentence a buyer of a compounded injectable most needs to read.

"May increase lifespan"

The NAD+ page is where the claims run furthest, and where Hone contradicts itself inside a single scroll.

The headline: "NAD+ is a crucial ally in your body's fight against aging. Supplementing with NAD+ injections may increase lifespan, boost strength and physical performance, help with weight loss, and more." $165 a month.

As of August 2026, a PubMed search for "nicotinamide adenine dinucleotide" or "NAD+" combined with an injected route and filtered to randomised controlled trials returns four records. ¹⁰ Only one actually gives NAD+ by an injected route: a 2026 placebo-controlled trial in heart failure caused by ischaemic cardiomyopathy. ¹¹ The others are a SIRT1-activator phase 1 study, a hypertonic-saline heart-failure trial, and a 2006 paper on ethanol elimination.

No randomised trial has measured lifespan, strength or weight loss with injected NAD+ in healthy adults. More fundamentally: no trial of any intervention has demonstrated an increase in human lifespan, because the follow-up required does not exist. "May increase lifespan" is not a weakly supported claim. It is a claim of a kind that no current human evidence can support.

And Hone knows. Scroll down the same page to the Warnings block and you find: "Multiple third-party studies have shown the health benefits of NAD+. While many of the studies used animal models and have not been proven in humans yet, clinical trials are ongoing."

That is an honest sentence. It is four hundred pixels below a sentence about lifespan, and it is set in the small type.

The glutathione page runs the same pattern more mildly. The biochemistry is right — glutathione is a tripeptide, it is a principal endogenous antioxidant, and it does support detoxification and T-cell function. "May extend lifespan" is bolted on beside it. A PubMed search for glutathione with longevity, lifespan or "life span", filtered to randomised trials, returns five records; all five test oral interventions and all five report antioxidant biochemistry rather than an ageing outcome. ¹²

Sermorelin, and the molecule Hone is thinking of

Sermorelin costs $130 a month and, unlike PT-141, it sits on the Premium tier — so the real bill is $285 a month before the lab panel.

The claim is specific enough to test: "When included as part of a comprehensive weight loss plan, sermorelin can help improve body composition, break down stored fat, and avoid the loss of muscle mass, which can be a detrimental effect of weight loss programs."

The final clause is a real clinical concern. Losing lean mass alongside fat during rapid weight loss is well documented and worth taking seriously; it has its own literature. The question is whether sermorelin does anything about it.

As of August 2026, a PubMed search for sermorelin filtered to randomised controlled trials returns 19 records, the newest published in 2005. ^{7 8} Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None measures fat mass, lean mass or body composition during weight loss.

ClinicalTrials.gov lists 27 studies with sermorelin as an intervention. Exactly one of them measures abdominal fat: NCT00675506, "Effectiveness of Growth Hormone Releasing Hormone in Reducing Abdominal Fat in People Who Are Obese", phase 2, completed, 60 participants. Open its intervention record and the drug is named "Growth hormone releasing hormone (GHRH) 1-44", other name TH9507. ⁹

TH9507 is tesamorelin. It is a different molecule — a GHRH 1-44 analogue rather than the 1-29 fragment — it reached phase 3 in HIV-associated lipodystrophy, and it holds an FDA approval. Sermorelin does not, and its trials went somewhere else entirely. The two are cousins that a search engine cannot tell apart, which is exactly why the growth-hormone secretagogue family needs reading one molecule at a time.

The one claim that survives, and what it costs

Compounded liraglutide, from $160 a month, Premium tier only.

The claim: "Compounded liraglutide is prescribed to support weight loss, helping patients lose up to 5-10% of their body weight."

SCALE Obesity and Prediabetes randomised 3,731 adults with obesity or overweight with co-morbidities to liraglutide 3.0 mg daily or placebo for 56 weeks. Mean weight loss: 8.0% against 2.6%. ^{1 2} Hone's stated range brackets the trial's own headline figure, and it is expressed as a range rather than as the best number available — which, in a category where every page quotes the top of the distribution, is worth pausing on.

There is a second thing to Hone's credit here that it never mentions. Liraglutide injection is still on FDA's drug shortage database — initially posted July 18, 2023, with Novo Nordisk presentations of Victoza and Saxenda still listed as current on August 6, 2026. Compounding a drug in genuine shortage is a materially different proposition from compounding one that came off the list, and Hone chose the former.

What the trial does not cover is Hone's product. SCALE tested Saxenda: a finished, approved drug with a National Drug Code, made by the company that ran the trial. No compounded liraglutide from any seller has been through a registered trial, and the compounded preparation is not the trial drug no matter how identical the molecule is. Hone's own page says as much, in the Warnings block, correctly.

The three numbers on every page

One last thing, because it runs across the whole site rather than one product.

Every Hone product page carries three statistics: 92% of patients "see an improvement in quality of life measures in 6 months such as having more energy, improved libido, and increase in strength"; 85% "see their mood improve as measured by the PHQ9 (depressive symptom index) after 6 months of treatment"; 70% "are still with Hone after 1 year of treatment. That's among the highest in health care."

They appear identically on the sermorelin page, the PT-141 page, the NAD+ page and the glutathione page. There is no study, no denominator, no time window beyond "6 months", no comparison group and no source anywhere on the site.

Which means the sermorelin buyer and the glutathione buyer are shown the same 92%, and neither number is about the product they are looking at. A retention figure and a self-reported wellbeing figure across a whole patient panel are not evidence for a molecule, and rendering them beside one is the oldest move in this category — a claim outrunning its evidence does not always take the form of a sentence.